Mayo Clinic | Strategic Alliance Partners

Latest from Mayo Clinic


Examining the Promise of Multicancer Early Detection Tests: Looking to the Future

July 26, 2023

In this seventh episode of OncChats: Examining the Promise of Multicancer Early Detection Tests, Toufic A. Kachaamy, MD, Madappa Kundranda, MD, PhD, and Niloy Jewel J. Samadder, MD, discuss the data that are still needed to inform optimal utilization of multicancer early detection tests and their potential cost effectiveness.

Birtamimab Pushes the Needle in AL Amyloidosis

July 26, 2023

Findings from an analysis of treatment patterns for patients with systemic amyloid light chain amyloidosis have demonstrated that several unmet needs exist, including timely diagnosis and limited survival outcomes for patients with advanced disease.

Patient Scenario 2: 1L Management of ES-SCLC Positive for Synaptophysin With a Ki-67 Score of 90%

July 24, 2023

Expert oncologists present the case of a 45-year-old woman with synaptophysin-positive, extensive-stage small-cell lung cancer with a Ki-67 score of 90%, who is treated with carboplatin, etoposide, and atezolizumab in the first-line setting, and provide their initial impressions.

Examining the Promise of Multicancer Early Detection Tests: Takeaways From the ECLIPSE Trial

July 19, 2023

In this sixth episode of OncChats: Examining the Promise of Multicancer Early Detection Tests, Toufic A. Kachaamy, MD, Madappa Kundranda, MD, PhD, and Niloy Jewel J. Samadder, MD, discuss important takeaways from the ECLIPSE study (NCT04136002), which evaluated a cell-free DNA blood-based test for colorectal cancer in an average-risk population.

Examining the Promise of Multicancer Early Detection Tests: Lessons Learned From PATHFINDER

July 12, 2023

In this fifth episode of OncChats: Examining the Promise of Multicancer Early Detection Tests, Toufic A. Kachaamy, MD, Madappa Kundranda, MD, PhD, and Niloy Jewel J. Samadder, MD, walk through the key lessons learned from the prospective, multicenter PATHINDER study (NCT04241796), which evaluated a multicancer early detection test developed by GRAIL.